Biobanking Market

Market Overview:

The global biobanking market size reached USD 64.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 101.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.2% during 2025-2033. The rising number of genomic research activities, increasing prevalence of chronic diseases, and rising focus on virtual biobank represent some of the key factors driving the market.

Biobanking refers to the process wherein samples of bodily fluid or tissue are collected, stored, annotated, and redistributed for research to improve the understanding of health and disease. It is a reliable hub of samples and enables access to a pool of high-quality samples and associated data. It is essential for the diagnosis and production of medicines for numerous disorders. It provides a basis for improving personalized medical approaches wherein effective biomarker identification is vital for disease diagnosis and prognosis. It serves as a mediator between donor and researcher for numerous research and different studies. It has high-quality control and assists in improving the reproducibility of various experiments. It also offers data generated through biosamples that is crucial for the digital transformation of health systems. As a result, biobanking is widely utilized in drug and biomarker development, clinical care for therapy, and clinical trials monitoring for the effects of drugs on eventual outcomes across the globe.

Biobanking Market Trends:

At present, the rising demand for biobanking due to the increasing number of genomic research activities represents one of the key factors supporting the growth of the market. Besides this, the growing number of biobanks across the globe, due to its potential to enhance the reproductivity and meaning of data generated by biomedical research, is offering a positive market outlook. Additionally, there is a rise in the prevalence of chronic diseases, such as diabetes, hypertension, cancer, heart attack, and respiratory disorders, among the masses around the world. This, coupled with the increasing demand for biobanking to develop diagnostics that can effectively identify pathogens, is propelling the growth of the market. Apart from this, the rising expenditure in advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, is offering lucrative growth opportunities to industry investors. Moreover, the increasing demand for biospecimens from clinical labs to develop assays for genetic testing is positively influencing the market. In addition, the growing focus on virtual biobank that minimizes time constraints, generates high revenue, and allows researchers to conduct the research smoothly is contributing to the growth of the market. Furthermore, key players are introducing a biobank software solution that assists in gaining visibility and improving the quality of the service provided to customers, which is strengthening the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biobanking market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on specimen type, biobank type, application and end user.

Specimen Type Insights:

• Blood Products
• Solid Tissue
• Cell Lines
• Nucleic Acid
• Others
   

The report has provided a detailed breakup and analysis of the biobanking market based on the specimen type. This includes blood products, solid tissue, cell lines, nucleic acid, and others. According to the report, blood products represented the largest segment.

Biobank Type Insights:

• Population-based Biobanks
• Disease-oriented Biobanks
   

A detailed breakup and analysis of the biobanking market based on the biobank type has also been provided in the report. This includes population-based biobanks and disease-oriented biobanks. According to the report, disease-oriented biobanks accounted for the largest market share.

Application Insights:

• Therapeutics
• Research
   

A detailed breakup and analysis of the biobanking market based on the application has also been provided in the report. This includes therapeutics and research. According to the report, research accounted for the largest market share.

End-User Insights:

• Academic Institutions
• Pharma and Biotech Companies
   

A detailed breakup and analysis of the biobanking market based on the end-user has also been provided in the report. This includes academic institutions and pharma and biotech companies. According to the report, academic institutions accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe was the largest market for biobanking. Some of the factors driving the Europe biobanking market included rising advancements in the stem cell and regenerative medicine research, increasing awareness about stem cell therapies, high demand for automated alarm monitoring devices, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global biobanking market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Brooks Automation Inc., Bay Biosciences LLC, Boca Biolistics, Ctibiotech, Cureline Inc., Firalis, Greiner Bio-One International GmbH, Hamilton Company, Merck KGaA, ProteoGenex Inc., Thermo Fisher Scientific Inc., VWR Corporation (Avantor Inc.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the biobanking market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global biobanking market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the biobanking industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.